Acellular soft tissue-derived matrices and methods for using same
Yen-Chen Huang, East Brunswick, NJ (US); Asia Ivery, Hammond Plains (CA); Bryan Choi, San Marcos, CA (US); Benjamin Schilling, Pittsburgh, PA (US); and Manh-Dan Ngo, Matawan, NJ (US)
Assigned to Musculoskeletal Transplant Foundation, Edison, NJ (US)
Filed by Musculoskeletal Transplant Foundation, Edison, NJ (US)
Filed on May 4, 2023, as Appl. No. 18/143,316.
Application 18/143,316 is a division of application No. 17/536,841, filed on Nov. 29, 2021, granted, now 11,779,610.
Application 17/536,841 is a division of application No. 16/782,653, filed on Feb. 5, 2020, granted, now 11,191,788, issued on Dec. 7, 2021.
Application 16/782,653 is a division of application No. 16/121,969, filed on Sep. 5, 2018, granted, now 10,596,201, issued on Mar. 24, 2020.
Application 16/121,969 is a division of application No. 15/388,428, filed on Dec. 22, 2016, granted, now 10,092,600, issued on Oct. 9, 2018.
Application 15/388,428 is a division of application No. 14/446,629, filed on Jul. 30, 2014, abandoned.
Claims priority of provisional application 61/860,043, filed on Jul. 30, 2013.
Prior Publication US 2023/0270794 A1, Aug. 31, 2023
1. A composition comprising: a delipidated, decellularized adipose tissue matrix derived from a first sample of adipose tissue which has been delipidated prior to decellularizing, wherein the delipidated, decellularized adipose tissue matrix contains a first proportion of lipids which is less than a second proportion of lipids contained in a processed adipose tissue derived from a second sample of adipose tissue which has been decellularized prior to delipidating; and a population of isolated viable adipose-derived stem cells (ASCs) seeded on the delipidated, decellularized adipose tissue matrix.